|
129. The pharmaceutical industry argues that because new drugs will not be developed unless
heavy development costs can be recouped in later sales, the current 20 years of protection
provided by patents should be extended in the case of newly developed drugs. However, in
other industries new-product development continues despite high development costs, a fact
that indicates that the extension is unnecessary.
Which of the following, if true, most strongly supports the pharmaceutical industry's
argument against the challenge made above?
(A) No industries other than the pharmaceutical industry have asked for an extension of the
20-year limit on patent protection.
(B) Clinical trials of new drugs, which occur after the patent is granted and before the new
drug can be marketed, often now take as long as 10 years to complete.
(C) There are several industries in which the ratio of research and development costs to
revenues is higher than it is in the pharmaceutical industry.
(D) An existing patent for a drug does not legally prevent pharmaceutical companies from
bringing to market alternative drugs, provided they are sufficiently dissimilar to the
patented drug.
(E) Much recent industrial innovation has occurred in products---for example, in the
computer and electronics industries---for which patent protection is often very ineffective.
大家莫讨厌我啊!我在逻辑区实在查不出来,只好麻烦各位了。问题是问支持P工业的观点(蓝色),我想此文的后半部分是不是根本就不用考虑?就是问题问的与however后面毫无关系是吗?是不是他说20年的专利需要再延续。而b就是说临床试验就花去10年。就这样就加强了,对吗?   |